摘要
目的:探讨P53蛋白和增殖相关抗原Ki67在非霍奇金淋巴瘤(NHL)中的表达及临床意义。方法:用免疫组织化学染色法(SP法)对129例NHL活检石蜡组织进行P53、Ki67检测,同时以CHOP方案化疗,评价疗效。观察P53和Ki67与NHL恶性程度、化疗疗效及PFS的关系。结果:129例NHL中,P53蛋白过度表达55例,占42.6%,Ki67表达101例,占78.3%;侵袭性NHL组的P53和Ki67表达均高于惰性淋巴瘤组(P<0.01)。全组LDH正常77例,异常52例,LDH异常组Ki67表达高于正常组(P<0.01);P53蛋白表达两组无显著性差异(P>0.05)。129例NHL接受CHOP方案化疗后,首次化疗有效组中的P53过度表达低于无效组(P<0.01);Ki67表达无显著性差异(P>0.05)。P53低表达组的中位PFS较高表达组长4.5个月;Ki67低表达组的中位PFS较高表达组长11个月。P53、Ki67表达与性别、发病部位、临床分期及免疫分型无相关性。结论:P53和Ki67与NHL的恶性程度、预后密切相关,可作为预测NHL患者的预后因素并指导治疗。
Objective：To measure the expression of P53 protein and proliferative antigen Ki-67 in non-Hodgkin＇s lymphoma （NHL） for the purpose of explore their expression and clinical value in NHL. Methods：The P53 and Ki-67 were measured by immunohistoehemistry on paraffin specimens in 129 cases of NHL. All patients were treated by CHOP regimen. To observate relationship of P53 and Ki-67 with malignant grading,chemotherapy and PFS. Results：The over-expression rates of P53 and Ki-67 were 42.6% （55/129） and 78. 3% （ 101/129）, respectively. The expressions of P53 and Ki-67 in aggressive NHL were higer than that in indolent NHL（P 〈 O. O1 ）. LDH was normal in 77 cases and abnormal in 52 cases. The expression of Ki-67 in LDH abnormal group was higer than that in LDH normal group （ P 〈 0.01 ）. The expression P53 in LDH abnormal group was as same as that in LDH normal group （ P 〉 0.05 ）. After CHOP regimen chemotherapy, the over-expression of P53 in remission group was lower than that in non-remission group （ P 〈 0.01 ）, but that of Ki-67 was same in two groups （ P 〉0.05）. The mean PFS was longer 4 months in low-expression group of I＇53 than that in over-expression group of p53. The mean PFS was longer 11 months in low-expression group of Ki-67 than that in over-expression group of Ki-67. The expression of P53 and Ki-67 was not related with sex, site of tumor growth, clinical stage and immunotype. Conclusion：P53 and Ki-67 are close related with malignant grading and prognosis in NHL. We may evaluate the prognosis and help to treat better through the combined measured of P53 and Ki-67 in NHL.
出处
《临床肿瘤学杂志》
CAS
2007年第2期100-102,共3页
Chinese Clinical Oncology
